Biodexa Pharmaceuticals Prices $10 Million U.S. Public Offering to Fund Pipeline

Biodexa Pharmaceuticals ( (BDRX) ) has shared an announcement.

On December 17–18, 2025, Biodexa Pharmaceuticals PLC launched and priced a best-efforts public offering of American Depositary Share (ADS) units and pre-funded units, structured with accompanying Series L warrants and pre-funded warrants, at combined prices of $3.28 and $3.2799 per unit respectively, for expected gross proceeds of about $10 million and net proceeds of roughly $8.75 million. The offering, conducted under an effective Form F-1 registration statement with Maxim Group LLC as sole placement agent, includes customary purchase and placement agreements, lock-up restrictions on new share issuances and variable-rate financings, and issuance of placement agent warrants, and is expected to close on or about December 19, 2025; Biodexa plans to use the proceeds to fund its development programs, working capital and general corporate purposes, bolstering liquidity after reporting £2.79 million in cash and cash equivalents as of September 30, 2025, although that financial figure is unaudited and subject to change.

The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.

Spark’s Take on BDRX Stock

According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.

Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.

To see Spark’s full report on BDRX stock, click here.

More about Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) is a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies targeting diseases with unmet medical needs. Its lead programs include eRapa for Familial Adenomatous Polyposis and non-muscle invasive bladder cancer, tolimidone for type 1 diabetes, and MTX110 for aggressive rare/orphan brain cancers. The company leverages three proprietary drug-delivery technologies and operates from its headquarters and R&D facility in Cardiff, UK.

Average Trading Volume: 979,292

Technical Sentiment Signal: Sell

Current Market Cap: $4.03M

Learn more about BDRX stock on TipRanks’ Stock Analysis page.